Article
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Cancer medicine - 1 Dec 2023
Uemura Takehiro, Kenmotsu Hirotsugu, Hazama Daisuke, Teraoka Shunsuke, Kobe Hiroshi, Azuma Koichi, Yamaguchi Teppei, Masuda Takeshi, Yokoyama Toshihide, Otsubo Kohei, Haratani Koji, Hayakawa Daisuke, Oki Masahide, Takemoto Shinnosuke, Ozaki Tomohiro, Akashi Yusaku, Hata Akito, Hashimoto Hiroya, Yamamoto Nobuyuki, Nakagawa Kazuhiko
Abstract excerpt
BACKGROUND: Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non-small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing for EGFR mutations, ALK fusions and ROS1 fusions. We conducted a prospective observational study (WJOG13620L) of follow-on next-generation sequencing of circulating tumor DNA (ctDNA)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.